These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 11926130)
1. Recent developments in peptide-based cancer therapeutics. Sehgal A Curr Opin Drug Discov Devel; 2002 Mar; 5(2):245-50. PubMed ID: 11926130 [TBL] [Abstract][Full Text] [Related]
2. Current strategies for the development of peptide-based anti-cancer therapeutics. Borghouts C; Kunz C; Groner B J Pept Sci; 2005 Nov; 11(11):713-26. PubMed ID: 16138387 [TBL] [Abstract][Full Text] [Related]
3. Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development. Hermiston TW; Kirn DH Mol Ther; 2005 Apr; 11(4):496-507. PubMed ID: 15771953 [TBL] [Abstract][Full Text] [Related]
4. Identification of cancer targets and therapeutics using phage display. Brissette R; Prendergast JK; Goldstein NI Curr Opin Drug Discov Devel; 2006 May; 9(3):363-9. PubMed ID: 16729733 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades. Bidwell GL; Raucher D Expert Opin Drug Deliv; 2009 Oct; 6(10):1033-47. PubMed ID: 19637980 [TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
7. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Okarvi SM Cancer Treat Rev; 2008 Feb; 34(1):13-26. PubMed ID: 17870245 [TBL] [Abstract][Full Text] [Related]
8. Antibody conjugates and therapeutic strategies. McCarron PA; Olwill SA; Marouf WM; Buick RJ; Walker B; Scott CJ Mol Interv; 2005 Dec; 5(6):368-80. PubMed ID: 16394252 [TBL] [Abstract][Full Text] [Related]
9. New approaches to the therapy of various tumors based on peptide analogues. Schally AV Horm Metab Res; 2008 May; 40(5):315-22. PubMed ID: 18491250 [TBL] [Abstract][Full Text] [Related]
10. More than one reason to rethink the use of peptides in vaccine design. Purcell AW; McCluskey J; Rossjohn J Nat Rev Drug Discov; 2007 May; 6(5):404-14. PubMed ID: 17473845 [TBL] [Abstract][Full Text] [Related]
11. Macromolecular therapeutics: emerging strategies for drug discovery in the postgenome era. Juliano RL; Astriab-Fisher A; Falke D Mol Interv; 2001 Apr; 1(1):40-53. PubMed ID: 14993337 [TBL] [Abstract][Full Text] [Related]
12. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Duncan R; Vicent MJ; Greco F; Nicholson RI Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S189-99. PubMed ID: 16113096 [TBL] [Abstract][Full Text] [Related]
15. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Workman P Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic peptides: technological advances driving peptides into development. Sato AK; Viswanathan M; Kent RB; Wood CR Curr Opin Biotechnol; 2006 Dec; 17(6):638-42. PubMed ID: 17049837 [TBL] [Abstract][Full Text] [Related]
17. New drugs in prostate cancer. Armstrong AJ; Carducci MA Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849 [TBL] [Abstract][Full Text] [Related]
18. The many futures for cell-penetrating peptides: how soon is now? Howl J; Nicholl ID; Jones S Biochem Soc Trans; 2007 Aug; 35(Pt 4):767-9. PubMed ID: 17635144 [TBL] [Abstract][Full Text] [Related]
19. Novel therapeutics for melanoma. Seetharamu N; Ott PA; Pavlick AC Expert Rev Anticancer Ther; 2009 Jun; 9(6):839-49. PubMed ID: 19496721 [TBL] [Abstract][Full Text] [Related]
20. Peptide-based drug design: here and now. Otvos L Methods Mol Biol; 2008; 494():1-8. PubMed ID: 18726565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]